Neurocrine Biosciences (NBIX) Tops Q2 EPS by 69c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq rise as tech stocks gain ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $168.43 +15.88%
Financial Fact:
Total other income: 1.55M
Today's EPS Names:
INM, TRI, CRVL, More
Financial Fact:
Total other income: 1.55M
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $1.65, $0.69 better than the analyst estimate of $0.96. Revenue for the quarter came in at $687.5 million versus the consensus estimate of $653.32 million.
GUIDANCE:
Neurocrine Biosciences sees FY2025 revenue of $2.5-2.55 billion, versus the consensus of $2.68 billion.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Arch Capital (ACGL) PT Raised to $106 at Keefe, Bruyette & Woods
- Sysco Corp. (SYY) Reports In-Line Q1 EPS
- DigitalOcean (DOCN) Tops Q3 EPS by 13c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
